Patents by Inventor Robert L. Coffman

Robert L. Coffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190240323
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 8, 2019
    Inventors: Gary S. OTT, Robert J. MILLEY, Robert L. COFFMAN, Radwan KIWAN, Holger KANZLER
  • Patent number: 10369168
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 6, 2019
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • Patent number: 10350290
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: July 16, 2019
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan Kiwan, Holger Kanzler
  • Publication number: 20190151462
    Abstract: The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 23, 2019
    Applicant: Dynavax Technologies Corporation
    Inventors: Robert L. COFFMAN, Stewart D. CHIPMAN, Radwan KIWAN, Samuel ZALIPSKY, Gary S. OTT
  • Publication number: 20190151345
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Application
    Filed: September 25, 2018
    Publication date: May 23, 2019
    Inventors: Cristiana GUIDUCCI, Robert L. COFFMAN
  • Publication number: 20180360954
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 20, 2018
    Inventors: Gary S. OTT, Robert J. MILLEY, Robert L. COFFMAN, Radwan KIWAN, Holger KANZLER
  • Patent number: 10111899
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 30, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • Publication number: 20180264023
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Inventors: Cristiana GUIDUCCI, Robert L. COFFMAN
  • Publication number: 20180169229
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 21, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Publication number: 20180161427
    Abstract: The present disclosure describes combination therapies comprising an anti-IL-10 antibody or antigen-binding fragment thereof and a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 14, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Elliot Keith CHARTASH, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Patent number: 9993495
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: June 12, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • Patent number: 9950064
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: April 24, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan R Kiwan, Holger Kanzler
  • Publication number: 20160346312
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Application
    Filed: May 23, 2016
    Publication date: December 1, 2016
    Inventors: Cristiana GUIDUCCI, Robert L. COFFMAN
  • Patent number: 9476053
    Abstract: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: October 25, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Tracy Matray, Cristiana Guiducci
  • Publication number: 20160213774
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Application
    Filed: January 22, 2016
    Publication date: July 28, 2016
    Inventors: Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan Kiwan, Holger Kanzler
  • Patent number: 9347064
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 24, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci
  • Patent number: 9333254
    Abstract: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 10, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Edith M. Hessel, Robert L. Coffman
  • Publication number: 20160003807
    Abstract: Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.
    Type: Application
    Filed: April 23, 2015
    Publication date: January 7, 2016
    Applicant: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Franck BARRAT, Robert L. COFFMAN, Cristiana GUIDUCCI
  • Publication number: 20150275216
    Abstract: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
    Type: Application
    Filed: February 3, 2015
    Publication date: October 1, 2015
    Inventors: Franck BARRAT, Robert L. COFFMAN, Tracy MATRAY, Cristiana GUIDUCCI
  • Publication number: 20150203850
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Application
    Filed: November 25, 2014
    Publication date: July 23, 2015
    Inventors: Franck BARRAT, Robert L. COFFMAN, Cristiana GUIDUCCI